Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Fusen Pharmaceutical Co., Ltd. has announced that its Piracetam Injection, aimed at treating memory loss and brain dysfunction, has been accepted by China’s National Medical Products Administration. This drug is part of a growing market for neurological medications and could significantly expand Fusen’s offerings in cerebrovascular and cognitive treatment. With sales in public medical institutions reaching RMB2.0 billion in 2023, the potential for Piracetam Injection is substantial.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.